

NIHR Performance Metrics - Delivering Clinical Research Quarter 2 (2016 - 2017)

Research Ethics Committee Reference	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One	Maximum Number Of Patients Agreed (Enter Same In	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Reason For Closure Of Trial
12/WS/0300	114081	A Randomized, DoubleBlind, PlaceboControlled, ParallelGroup Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome-ODYSSEY OUTCOMES	Number Agreed	25	25	Not Available / Not Agreed		22	11/11/2015	Recruitment Finished
13/SC/0268	124775	An open-label, crossover, interventional Phase IV study to compare the ease of use of tobramycin inhalation powder with tobramycin inhalation solution and nebulized colistimethate for the treatment of pulmonary Pseudomonas aeruginosa in patients with	Number Agreed	5	5	Not Available / Not Agreed		5	20/10/2015	Withdrawn By Sponsor
14/NW/0130	149373	A randomised, double blind, multi-center, placebo-controlled study to evaluate the efficacy, safety, and tolerability of NT100 in pregnant women with a history of unexplained recurrent pregnancy loss (RPL)	Number Agreed	5	5	Not Available / Not Agreed		17	26/10/2015	Recruitment Finished
14/WM/0170	154982	A Phase 3, Randomized Study to Evaluate the Efficacy of Momelotinib versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis	Number Agreed	2	2	Not Available / Not Agreed		3	12/01/2016	Recruitment Finished
14/EE/1235	159181	A PHASE 2 RANDOMIZED, DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY, IN COMBINATION WITH OSELTAMIVIR VERSUS OSELTAMIVIR FOR TREATMENT OF SEVERE? INFLUENZA A INFECTION	Number Agreed	2	2	Not Available / Not Agreed		0	02/02/2016	Withdrawn By Host
14/NW/0119	159181	A 4 week phase 2a, multicentre, randomised, double-blind, placebo-controlled add-on study into safety, tolerability and efficacy of 200 mg t.i.d. of PL37 in patients with peripheral neuropathic pain of diabetic origin treated with pregabalin or gabap	Number Agreed	10	10	Not Available / Not Agreed		0	16/03/2016	Withdrawn By Sponsor
14/SC/0033	146569	PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-04950615, IN REDUCING THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS	Number Agreed	6	6	Not Available / Not Agreed		5	26/01/2016	Recruitment Finished
15/SW/0197	181752	GO29432: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF MPDL3280A (ANTI-PDL1 ANTIBODY) COMPARED WITH GEMCITABINE+CISPLATIN OR CARBOPLATIN FOR PD-L1-SELECTED, CHEMOTHERAPY NAIVE PATIENTS WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER	Number Agreed	4	4	Not Available / Not Agreed		0	19/04/2016	Recruitment Finished
14/NW/1053	157943	A Randomized, Double Blind, Placebo-Controlled, Dose Titration, Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 494372 Administered Subcutaneously to Patients with High Lipoprotein(a)	Number Agreed	3	3	Not Available / Not Agreed		3	08/12/2015	Recruitment Finished
15/LO/0032	148409	RANDOMIZED, MULTICENTER, PHASE III, OPEN LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT NA?VE ANAPLASTIC LYMPHOMA KINASE?POSITIVE ADVANCED NON? SMALL CELL LUNG CANCER	Number Agreed	2	2	Not Available / Not Agreed		1	08/12/2015	Recruitment Finished
14/LO/0324	146711	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin? in the Management of Chronic Lung Infections with Pseudomonas aeruginosa in Subjects with Non-Cystic Fibrosis Bronchiectasis, includin	Number Agreed	3	3	Not Available / Not Agreed		1	06/01/2016	Recruitment Finished
15/LO/0967	178036	INNOVATE Study: A randomized, double-blind, placebo-controlled, phase 3 study of ibrutinib or placebo in combination with Rituximab in Subjects with Waldenstr?m?s Macroglobulinemia	Number Agreed	5	5	Not Available / Not Agreed		0	13/01/2016	Recruitment Finished
14/NE/1214	162696	A Randomised, OpenLabel, Multicenter, Phase 2 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced NonSquamous No	Number Agreed	6	10	Not Available / Not Agreed		0	10/06/2016	Recruitment Finished
13/SC/0490	135889	A PHASE III, Randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of lebrikizumab in adolescent patients with severe uncontrolled asthma who are on inhaled corticosteroids and a second controller medicat	Number Agreed	3	10	Not Available / Not Agreed		2	30/06/2016	Withdrawn By Sponsor

13/NJ/0148	102251	A phase II, randomised, double blind, placebo controlled, multicentre trial to assess the oral corticosteroidsparing effect of lebrikizumab in patients with with severe corticosteroiddependant asthma	Number Agreed	12	12	Not Available / Not Agreed	10	30/06/2016	Withdrawn By Sponsor
16/LO/0026	195795	A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Boosted Atazanavir or Darunavir plus either Emtricitabine/Tenofovir or Abacavir/Lamivudine to GS 9883/Emtricitabine/Tenofovir Alafena	Number Agreed	6	6	Not Available / Not Agreed	3	23/06/2016	Recruitment Finished
16/LO/0029	195696	A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Na?ve Adults	Number Agreed	3	3	Not Available / Not Agreed	5	15/07/2016	Recruitment Finished
15/LO/1163	181430	A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects who are Virologically Suppressed on Regimens Containing ABC/ETC	Number Agreed	6	6	Not Available / Not Agreed	6	29/05/2016	Recruitment Finished